Shots:

• The first patient has been dosed in a P-II investigator-initiated (IPAX-Linz) study evaluating TLX101 + external beam radiation therapy (EBRT) in patients with recurrent HGG incl. GBM. The study was led by Professor Josef Pichler at Kepler University Hospital in Linz, Austria
• The (IPAX-1) study results showed a favorable safety profile along with an encouraging preliminary therapeutic effect & continues to provide benefits to patients in 2L settings at neuro-oncology sites in the EU
• TLX101 (4-L-[131I] iodo-phenylalanine) has received ODD from the US FDA & EMA that targets L-type amino acid transporter 1 (LAT-1) for the treatment of malignant tumours incl. HGG/GBM

Ref: PRNewswire | Image: Telix